<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02161939</url>
  </required_header>
  <id_info>
    <org_study_id>AI444-257</org_study_id>
    <nct_id>NCT02161939</nct_id>
  </id_info>
  <brief_title>A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C</brief_title>
  <official_title>A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Subjects With Chronic Hepatitis C and Decompensated Cirrhosis or Post-Liver Transplant Subjects With Chronic Hepatitis C Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this program is to provide DCV for 24 weeks to be given in
      combination with SOF to subjects with chronic hepatitis C with decompensated cirrhosis or
      post-liver transplant subjects with chronic hepatitis C recurrence with either advanced
      fibrosis or fibrosing cholestatic hepatitis and who have a serious or immediately
      life-threatening condition or experienced an event that has decreased their life expectancy
      to &lt;12 months, therefore, no research hypothesis will be tested and no specific endpoints
      are defined. However, safety data will be collected throughout the study as well as efficacy
      data
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <phase>N/A</phase>
  <study_type>Expanded Access</study_type>
  <study_design>N/A</study_design>
  <condition>Chronic Hepatitis C</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir (BMS-790052)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Patients chronically infected with Hepatitis C

          -  Subjects who received a liver transplant, have chronic hepatitis C virus (HCV)
             recurrence and advanced fibrosis (Metavir F3-F4) or fibrosing cholestatic hepatitis

          -  Subjects with decompensated cirrhosis defined by Child-Pugh Class C

        Exclusion Criteria:

          -  Patients who are &lt;18 years old

          -  Clinical or pathologic evidence of acute ongoing liver graft rejection

          -  Creatinine clearance (CrCl) â‰¤30 mL/min (as estimated by Cockcroft and Gault formula)

          -  Patients who have contraindications to either Daclatasvir (DCV) or Sofosbuvir (SOF)

          -  Patients who are pregnant or Women of Child Bearing Potential who are not using
             required contraception
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HCV-TARGET/University of Florida -- Angie Bauer</last_name>
    <email>bauera@medicine.ufl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lauren Morelli</last_name>
    <email>lauren.morelli@medicine.ufl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Hugo Vargas, Site 0002</last_name>
      <phone>480-342-1010</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>USC - Keck Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Saro Khemichian, Site 0019</last_name>
      <phone>323-442-6171</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Joseph Lim, Site 0009</last_name>
      <phone>203-737-6063</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Conseuelo Soldevila-Pico, Site 0004</last_name>
      <phone>352-273-9465</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Piedmont Transplant</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Devina Bhasin, Site 0021</last_name>
      <phone>404-548-0937</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul Kwo, Site 0010</last_name>
      <phone>317-274-3090</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Shobha Joshi, Site 0013</last_name>
      <phone>504-842-4015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center, Inc.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul Thuluvath, Site 0024</last_name>
      <phone>410-332-9308</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mass General</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ray Chung, Site 0008</last_name>
      <phone>617-643-0446</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Memorial Medical Center, University Campus</name>
      <address>
        <city>Worchester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Isabel Zacharias, Site 0023</last_name>
      <phone>508-856-3068</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Stuart Gordon, Site 0011</last_name>
      <phone>313-916-9465</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul Gaglio, Site 0017</last_name>
      <phone>718-920-4644</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Robert Brown, Site 0007</last_name>
      <phone>212-305-0662</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Arun Jesudian, Site 0018</last_name>
      <phone>646-962-9358</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UNC</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jama Darling, Site 0014</last_name>
      <phone>919-933-8938</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolinas Healthcare Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Philipe Zamor, Site 0022</last_name>
      <phone>704-355-6649</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadephia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rajender Reddy, Site 0005</last_name>
      <phone>215-662-4311</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Specialist of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Joseph Galati, Site 0003</last_name>
      <phone>713-634-5110</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Richard Sterling, Site 0016</last_name>
      <phone>804-828-9034</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne Larson, Site 0020</last_name>
      <phone>206-215-1437</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/investigator_sponsored_research/Pages/expanded-access-program.aspx</url>
    <description>EAP Investigator Requests</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 19, 2015</lastchanged_date>
  <firstreceived_date>June 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
